Prostate cancer: BRCA2 carriers respond to platinum-based chemotherapy
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- In men with castration-resistant prostate cancer (PCa), breast cancer 2 (BRCA2) carriers showed an improved response to platinum-based chemotherapy compared with non-carriers.
Why this matters
- BRCA2-associated breast and ovarian cancers are sensitive to platinum-based chemotherapy.
- It has been unknown whether BRCA2-associated PCa also responds favorably.
- Platinum agents have shown little benefit in the treatment of PCa, except for small cell PCa.
- The response rate observed in the present study is higher than that observed in previous studies of docetaxel-refractory castration-resistant PCa, including the cabazitaxel trial.
- The results suggest benefit in determining BRCA2 status and personalizing treatment with carboplatin for mutation carriers.
- In this retrospective study, 141 patients with metastatic castration-resistant PCa received at ...